T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation for a Patient With Tcf3-Hlf-Positive Acute Lymphoblastic Leukemia Extramedullary Relapse After Unrelated Bone Marrow Transplantation.
Nobuhisa TakahashiKazuhiro MochizukiShogo KobayashiYoshihiro OharaShingo KudoYuya SaitoKazuhiko IkedaHitoshi OhtoAtsushi KikutaHideki SanoPublished in: Journal of pediatric hematology/oncology (2022)
TCF3-HLF-positive B-cell precursor acute lymphoblastic leukemia (BCP-ALL) has an extremely poor prognosis. A 2-year-old boy with TCF3-HLF-positive BCP-ALL had an isolated extramedullary relapse in multiple bones after allogeneic hematopoietic stem cells transplantation (HSCT) from a human leukocyte antigen-matched unrelated donor. In this study, he received a T-cell-replete haploidentical HSCT (TCR-haplo-HSCT) from his father when in nonremission state, which resulted in a sustained complete remission for over 3 years. Immune therapies for patients with an extramedullary relapse of TCF3-HLF-positive BCP-ALL have been attempted; however, long-term efficacies of these therapies remain unknown. Our TCR-haplo-HSCT may be an effective therapeutic option for such patients.
Keyphrases
- bone marrow
- acute lymphoblastic leukemia
- poor prognosis
- hematopoietic stem cell
- stem cell transplantation
- stem cells
- end stage renal disease
- cord blood
- peripheral blood
- free survival
- regulatory t cells
- ejection fraction
- endothelial cells
- cell therapy
- allogeneic hematopoietic stem cell transplantation
- chronic kidney disease
- acute myeloid leukemia
- prognostic factors
- immune response
- rheumatoid arthritis
- case report
- dendritic cells